Xiaohua Zeng

New Capabilities

Lead investigator presenting Poster 1776P at ESMO 2026

Innovent presented Phase 2 results at the European Society for Medical Oncology (ESMO) congress showing its experimental HER2-targeting antibody-drug conjugate (ADC), IBI354, produced a 95% confirmed response rate in first-line HER2-positive metastatic breast cancer. All 20 patients responded to IBI354 plus pertuzumab, and none developed interstitial lung disease (ILD), the lung inflammation that is a known risk with the current standard drug.

Updated 1 hour ago